Incidence and clinical characteristics of the metabolic syndrome in patients with coronary artery disease

Coronary Artery Disease

Volumn 14, Issue 3, 2003, Pages 207-212

  Solymoss, Bela Charles ^a   Bourassa, Martial G ^a   Lespérance, Jacques ^a   Levesque, Sylvie ^a   Marcil, Michel ^b   Varga, Susan ^c   Campeau, Lucien ^a  

^a MONTREAL HEART INSTITUTE   (Canada)

^b MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^c MONTREAL GENERAL HOSPITAL   (Canada)

Author keywords

Coronary artery disease; Metabolic syndrome

Indexed keywords

ANTICOAGULANT AGENT; ANTIDIABETIC AGENT; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CHOLESTEROL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; THIAZIDE DIURETIC AGENT; TRIACYLGLYCEROL;

ADULT; AGED; ALCOHOL CONSUMPTION; ANGIOCARDIOGRAPHY; ARTICLE; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; CORONARY ARTERY OBSTRUCTION; DIABETES MELLITUS; EXERCISE; FAMILY HISTORY; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; INCIDENCE; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; OBESITY; PRIORITY JOURNAL; RISK FACTOR;

EID: 0037614907     PISSN: 09546928     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mca.0000065744.52558.9f     Document Type: Article

References (32)

1. Reaven GM. Banting Lecture 1988. Role of insulin resistance in human disease. Diabetes 1988; 37:1595-1607.
2. Haffner SM, Stern MP, Hazuda HP, Mitchell BD, Patterson JK. Cardiovascular risk factors in confirmed prediabetic individuals. Does the clock for coronary heart disease start ticking before the onset of clinical diabetes? JAMA 1990; 263:2893-2898.
3. Reaven GM. Syndrome X: 6 years later. J Intern Med 1994; 736 (suppl):13-22.
4. Depres JP, Marette A. Relation of components of insulin resistance syndrome to coronary disease risk. Curr Opin Lipidol 1994; 5:274-289.
5. Proietto J, Filippis A, Nakhla C, Clark S. Nutrient-induced insulin resistance. Mol Cell Endocrinol 1999; 151:143-149.
6. Timar O, Sestier F, Levy E. Metabolic Syndrome X: a review. Can J Cardiol 2000; 6:779-789.
7. Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis. Epidemiology, pathophysiology and management. JAMA 2002; 287:2570-2581.
8. Meigs JB, D'Agostino RB Sr, Wilson PW, Cupples LA, Nathan DM, Singer DE. Risk variable clustering in the insulin resistance syndrome. The Framingham Offspring Study. Diabetes 1997; 46:1594-1600.
9. Hauner H. Insulin resistance and the metabolic syndrome - a challenge of the new millenium. Eur J Clin Nutr 2002; 56 (suppl 1):S25-S29.
10. Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001; 285:2486-2497.
11. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults. Findings from the Third National Health and Nutrition Examination Survey. JAMA 2002; 287:356-359.
12. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28:412-419.
13. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 1997; 20:1183-1197.
14. Lemieux I, Pascot A, Couillard C, Lamarche B, Tchernof A, Almeras N, et al. Hypertriglyceridemic waist. A marker of the atherogenic triad (hyperinsulinemia; hyperapolipoprotein B; small, dense LDL) in men? Circulation 2000; 102:179-184.
15. Han TS, van Leer EM, Seidell JC. Waist circumference action levels in the identification of cardiovascular risk factors: prevalence study in a random sample. Br Med J 1995; 311:1401-1405.
16. Imbeault P, Lemieux S, Prudhomme D, Tremblay A, Nadeau A, Despres JP, et al. Relationship of visceral adipose tissue to metabolic risk factors for coronary heart disease: is there a contribution of subcutaneaous fat cell hypertrophy? Metabolism 1999; 48:355-362.
17. Howard BV. Insulin resistance and lipid metabolism. Am J Cardiol 1999; 84:28J-32J.
18. Sniderman AD, Scantlebury T, Cianflone K. Hypertriglyceridemic hyperapob: the unappreciated atherogenic dyslipoproteinemia in type 2 diabetes mellitus. Arch Intern Med 2001; 135:447-459.
19. Boden G, Shulman GI. Free fatty acids in obesity and type 2 diabetes: defining their role in the development of insulin resistance and beta-cell dysfunction. Eur J Clin Invest 2002; 32 (suppl 3):14-23.
20. Ahima RS, Flier JS. Adipose tissue as an endocrine organ. Trends Endocrinol Metab 2000; 11:327-332.
21. Shuldiner AR, Yang R, Gong DW. Resistin, obesity and insulin resistance - the emerging role of the adipocyte as an endocrine organ. N Engl J Med 2001; 345:1345-1346.
22. Steppan CM, Bailey ST, Bhat ST, Brown EJ, Banerjee RR, Wright CM, et al. The hormone resistin links obesity to diabetes. Nature 2001; 409:307-312.
23. Hoist D, Grimaldi PA. New factors in the regulation of adipose tissue differentiation and metabolism. Curr Opin Lipidol 2002; 13:241-246.
24. McTernan CL, McTernan PG, Harte AL, Levick PL, Barnett AH, Kumar S. Resistin, central obesity and type 2 diabetes. Lancet 2002; 359:46-47.
25. Greenberg AS, McDaniel ML. Identifying links between obesity, insulin resistance and beta-cell function: potential role of adipocyte derived cytokines in the pathogenesis of type 2 diabetes. Eur J Clin Invest 2002; 32 (suppl 3):24-34.
26. Chambers JC, Eda S, Bassett P, Karim Y, Thompson SG, Gallimore JR, et al. C-reactive protein, insulin resistance, central obesity, and coronary heart disease risk in Indian Asians from the United Kingdom compared with European whites. Circulation 2001; 104:145-150.
27. Frohlich M, Imhof A, Berg G, Hutchison WL, Pepys MB, Boeing H, et al. Association between C-reactive protein and features of the metabolic syndrome: a population based study. Diabetes Care 2000; 23:1835-1839.
28. Dixon JB, Dixon ME, O'Brien PE. Alcohol consumption in the severely obese: relationship with the metabolic syndrome. Obes Res 2002; 10:245-251.
29. Dobiasova M, Frohlich J. The plasma parameter log (TG/HDL-C) as an atherogenic index: correlation with lipoprotein particle size and esterification rate in apoB-lipoprotein-depleted plasma (FER(HDL)). Clin Biochem 2001; 34:583-588.
30. Pascot A, Lemieux I, Bergeron J, Tremblay A, Nadeau A, Prud'homme D, et al. HDL particle size: a marker of the gender difference in the metabolic risk profile. Atherosclerosis 2002; 160:399-406.
31. Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis. Epidemiology, pathophysiology and management. JAMA 2002; 287:2570-2581.
32. Resnick HE, Howard BV. Diabetes and cardiovascular disease. Annu Rev Med 2002; 53:245-267.